<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564471</url>
  </required_header>
  <id_info>
    <org_study_id>790117</org_study_id>
    <nct_id>NCT02564471</nct_id>
  </id_info>
  <brief_title>Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.</brief_title>
  <acronym>MALRAB</acronym>
  <official_title>Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-exposure Prophylaxis. A Randomized, Open Label, Trial in Healthy US Adults Age 18-60 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Upstate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kansas State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York - Upstate Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune&#xD;
      response generated by rabies vaccine when administered for post-exposure prophylaxis. This&#xD;
      study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies&#xD;
      immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis&#xD;
      regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rabies is present on all continents where U.S. military personnel deploy, including countries&#xD;
      where malaria is also endemic and where U.S. military personnel are required to take malaria&#xD;
      prophylaxis. Rabies post-exposure prophylaxis in unvaccinated individuals who are not on&#xD;
      malaria prophylaxis consists of four, 1.0-mL intramuscular (IM) injections of the purified&#xD;
      chick embryo cell (PCECV) rabies vaccine on days 0, 3, 7, and 14. The current Advisory&#xD;
      Committee on Immunization Practices (ACIP) guidelines recommend that exposed persons who are&#xD;
      taking malaria prophylaxis should receive a fifth dose of rabies vaccine 28 days after the&#xD;
      exposure. These guidelines do not differentiate between drugs used for malaria prophylaxis&#xD;
      This study will administer the post-exposure regimen to volunteers from a US population of&#xD;
      military age who are taking one of three malaria prophylaxis regimens or no malaria&#xD;
      prophylaxis. The goal of this study is to asses if individuals on malaria prophylaxis achieve&#xD;
      the required rabies titer after completion of the four dose regimen.&#xD;
&#xD;
      Obtaining rabies vaccine and rabies immune globulin in a deployed setting can be challenging.&#xD;
      A full understanding of the requirements for protecting exposed individuals is necessary for&#xD;
      appropriate decision making in a resource-constrained environment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2016</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) 14 Days Post Fourth Dose Post Exposure Prophylaxis (PEP) With Purified Chick Embryo Cell Vaccine (PCECV) in Each Malaria Prophylaxis Group Compared to Control to Determine if a Fifth Dose of PEP Would Add Value</measure>
    <time_frame>6 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and at 4 weeks for Rabies Group</time_frame>
    <description>Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21, and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3,7 and 14 (dose 4). Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of &gt;0.5 IU/ml against rabies virus as protective. Descriptive analyses were based on samples taken 14 days after dose 4, (e.g., at 6 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Arms and at 4 weeks for Rabies Arm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT Over Protective Titer Prior to Third Dose of PCECV</measure>
    <time_frame>21 days for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and 7 days for Rabies Arm</time_frame>
    <description>Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3, 7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of &gt;0.5 IU/ml against rabies virus as protective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT Over Protective Titer Prior Fourth Dose of PCECV</measure>
    <time_frame>28 days for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and 14 days for Rabies Arm</time_frame>
    <description>Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3, 7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of &gt;0.5 IU/ml against rabies virus as protective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT Over Protective Titer 28 Days Post Fourth Dose of PCECV</measure>
    <time_frame>Up to 8 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and up to 6 weeks for Rabies Arm</time_frame>
    <description>Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3,7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of &gt;0.5 IU/ml against rabies virus as protective.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Rabies</condition>
  <arm_group>
    <arm_group_label>Chloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atovaquone and Proguanil (Malarone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rabies</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>FDA approve dosing schedule</description>
    <arm_group_label>Chloroquine</arm_group_label>
    <other_name>Chloroquine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovaquone and Proguanil</intervention_name>
    <description>FDA approve dosing schedule</description>
    <arm_group_label>Atovaquone and Proguanil (Malarone)</arm_group_label>
    <other_name>Malarone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>FDA approve dosing schedule</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <other_name>Doxycycline Hyclate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabies Vaccine</intervention_name>
    <description>FDA approve dosing schedule</description>
    <arm_group_label>Atovaquone and Proguanil (Malarone)</arm_group_label>
    <arm_group_label>Chloroquine</arm_group_label>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_label>Rabies</arm_group_label>
    <other_name>RabAvert</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide signed and dated informed consent form.&#xD;
&#xD;
          2. Willing to comply with all study procedures and be available for the duration of the&#xD;
             study.&#xD;
&#xD;
          3. Male or female, aged ≥ 18 to ≤ 60 years on day of inclusion.&#xD;
&#xD;
          4. In good general health based on medical history and physical exam&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is pregnant, or lactating, or of childbearing potential (to be considered of&#xD;
             non-childbearing potential, a female must be post-menopausal for at least 1 year,&#xD;
             surgically sterile, or using an effective method of contraception or abstinence from&#xD;
             at least 4 weeks prior to the first vaccination and until at least 4 weeks after the&#xD;
             last vaccination.&#xD;
&#xD;
          2. Participation in the 4 weeks preceding the first trial vaccination, or planned&#xD;
             participation during the present trial period, in another clinical trial investigating&#xD;
             a vaccine, drug, medical device, or medical procedure.&#xD;
&#xD;
          3. Previous history of receiving the rabies vaccine.&#xD;
&#xD;
          4. Previous history of receiving rabies immune globulin.&#xD;
&#xD;
          5. Any major psychiatric disorder, such as severe depression, severe anxiety disorder,&#xD;
             psychosis, schizophrenia, other major psychiatric disorders, or seizures. History of&#xD;
             mild depression or anxiety disorder that are well controlled are not exclusion&#xD;
             criteria.&#xD;
&#xD;
          6. Use of any immunosuppressive drug at the time of the study or 30 days previously.&#xD;
             Topical steroids will not be considered an immunosuppressive drug and their use will&#xD;
             not be considered an exclusion criteria.&#xD;
&#xD;
          7. Any immunosuppressive disorder, such as HIV infection, common variable&#xD;
             immunodeficiency, active cancers or chemotherapy.&#xD;
&#xD;
          8. History of renal insufficiency or requiring dialysis.&#xD;
&#xD;
          9. Have any condition that would, in the opinion of the site investigator, place the&#xD;
             subject at an unacceptable risk of injury or render the subject unable to meet the&#xD;
             requirements of the protocol.&#xD;
&#xD;
         10. Identified as an employee of the Investigator or study center, with direct involvement&#xD;
             in the proposed study or other studies under the direction of that Investigator or&#xD;
             study center, as well as family members (i.e., immediate, husband, wife and their&#xD;
             children, adopted or natural) of the employee or the Investigator.&#xD;
&#xD;
         11. Previous adverse reaction to any of the antimalarial drugs used in this study.&#xD;
&#xD;
        Temporary Exclusion Criteria: Moderate or severe acute illness/infection (according to&#xD;
        investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on day 0.. A&#xD;
        prospective subject should not be included in the study until the condition has resolved or&#xD;
        the febrile event has subsided. If the delay for the febrile illness exceeds the window&#xD;
        between screening and vaccination, or if deemed necessary by the investigator, a&#xD;
        prospective subject may be re-screened once the fever has resolved.&#xD;
&#xD;
        Recent or scheduled receipt of any vaccine 4 weeks prior to day 0.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Endy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York - Upstate Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State University of New York, Upstate Medical University (SUNY-UMU)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Endy TP, Keiser PB, Cibula D, Abbott M, Ware L, Thomas SJ, Polhemus ME. Effect of Antimalarial Drugs on the Immune Response to Intramuscular Rabies Vaccination Using a Postexposure Prophylaxis Regimen. J Infect Dis. 2020 Mar 2;221(6):927-933. doi: 10.1093/infdis/jiz558.</citation>
    <PMID>31743394</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <results_first_submitted>December 1, 2020</results_first_submitted>
  <results_first_submitted_qc>March 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2021</results_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York - Upstate Medical University</investigator_affiliation>
    <investigator_full_name>Timothy Endy, MD MPH</investigator_full_name>
    <investigator_title>Chair, Department of Microbiology and Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Atovaquone</mesh_term>
    <mesh_term>Proguanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02564471/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02564471/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02564471/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy adults aged 18 to 60 were recruited from 11-Nov-2016 to 07-Jun-2018 in and around the study site in Syracuse, New York</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Chloroquine</title>
          <description>Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)&#xD;
Chloroquine: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
        </group>
        <group group_id="P2">
          <title>Atovaquone and Proguanil (Malarone)</title>
          <description>Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Atovaquone and Proguanil: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
        </group>
        <group group_id="P3">
          <title>Doxycycline</title>
          <description>Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Doxycycline: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
        </group>
        <group group_id="P4">
          <title>Rabies</title>
          <description>RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Group 1: 1 subject excluded from analysis due to presence of rabies antibody titer at baseline; 1 excluded due to use of steroids during the study.&#xD;
Group 3: 1 subject excluded from analysis due to presence of rabies antibody titer at baseline</population>
      <group_list>
        <group group_id="B1">
          <title>Chloroquine</title>
          <description>Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)&#xD;
Chloroquine: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
        </group>
        <group group_id="B2">
          <title>Atovaquone and Proguanil (Malarone)</title>
          <description>Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Atovaquone and Proguanil: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
        </group>
        <group group_id="B3">
          <title>Doxycycline</title>
          <description>Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Doxycycline: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
        </group>
        <group group_id="B4">
          <title>Rabies</title>
          <description>RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Group 1: 3 subjects withdrew; 1 subject was excluded from analysis due to presence of rabies antibody titer at baseline; 1 subject was excluded due to use of steroids during the study.&#xD;
Group 2: 3 subjects withdrew. Group 3: 3 subjects withdrew; 1 subject was excluded from analysis due to presence of rabies antibody titer at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with data available at both baseline and post baseline assessments</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) 14 Days Post Fourth Dose Post Exposure Prophylaxis (PEP) With Purified Chick Embryo Cell Vaccine (PCECV) in Each Malaria Prophylaxis Group Compared to Control to Determine if a Fifth Dose of PEP Would Add Value</title>
        <description>Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21, and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3,7 and 14 (dose 4). Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of &gt;0.5 IU/ml against rabies virus as protective. Descriptive analyses were based on samples taken 14 days after dose 4, (e.g., at 6 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Arms and at 4 weeks for Rabies Arm).</description>
        <time_frame>6 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and at 4 weeks for Rabies Group</time_frame>
        <population>Group 1: 1 subject was excluded from analysis due to presence of rabies antibody titer at baseline, 1 was excluded due to use of steroids during the study; Group 2: 1 subject completed primary endpoint but did not complete the study; Group 3: 1 subject was excluded from analysis due to presence of rabies antibody titer at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine</title>
            <description>Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)&#xD;
Chloroquine: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
          <group group_id="O2">
            <title>Atovaquone and Proguanil (Malarone)</title>
            <description>Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Atovaquone and Proguanil: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
          <group group_id="O3">
            <title>Doxycycline</title>
            <description>Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Doxycycline: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
          <group group_id="O4">
            <title>Rabies</title>
            <description>RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) 14 Days Post Fourth Dose Post Exposure Prophylaxis (PEP) With Purified Chick Embryo Cell Vaccine (PCECV) in Each Malaria Prophylaxis Group Compared to Control to Determine if a Fifth Dose of PEP Would Add Value</title>
          <description>Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21, and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3,7 and 14 (dose 4). Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of &gt;0.5 IU/ml against rabies virus as protective. Descriptive analyses were based on samples taken 14 days after dose 4, (e.g., at 6 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Arms and at 4 weeks for Rabies Arm).</description>
          <population>Group 1: 1 subject was excluded from analysis due to presence of rabies antibody titer at baseline, 1 was excluded due to use of steroids during the study; Group 2: 1 subject completed primary endpoint but did not complete the study; Group 3: 1 subject was excluded from analysis due to presence of rabies antibody titer at baseline</population>
          <units>IU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="1.62"/>
                    <measurement group_id="O2" value="7.95" spread="0.81"/>
                    <measurement group_id="O3" value="8.51" spread="0.94"/>
                    <measurement group_id="O4" value="10.26" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT Over Protective Titer Prior to Third Dose of PCECV</title>
        <description>Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3, 7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of &gt;0.5 IU/ml against rabies virus as protective.</description>
        <time_frame>21 days for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and 7 days for Rabies Arm</time_frame>
        <population>Group 1: 1 subject completed all doses of vaccine but did not complete the study; Group 2: 2 subjects completed all doses of vaccine but did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine</title>
            <description>Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)&#xD;
Chloroquine: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
          <group group_id="O2">
            <title>Atovaquone and Proguanil (Malarone)</title>
            <description>Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Atovaquone and Proguanil: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
          <group group_id="O3">
            <title>Doxycycline</title>
            <description>Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Doxycycline: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
          <group group_id="O4">
            <title>Rabies</title>
            <description>RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
        </group_list>
        <measure>
          <title>GMT Over Protective Titer Prior to Third Dose of PCECV</title>
          <description>Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3, 7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of &gt;0.5 IU/ml against rabies virus as protective.</description>
          <population>Group 1: 1 subject completed all doses of vaccine but did not complete the study; Group 2: 2 subjects completed all doses of vaccine but did not complete the study.</population>
          <units>IU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.62"/>
                    <measurement group_id="O2" value="0.11" spread="0.40"/>
                    <measurement group_id="O3" value="0.16" spread="0.72"/>
                    <measurement group_id="O4" value="0.17" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT Over Protective Titer Prior Fourth Dose of PCECV</title>
        <description>Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3, 7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of &gt;0.5 IU/ml against rabies virus as protective.</description>
        <time_frame>28 days for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and 14 days for Rabies Arm</time_frame>
        <population>Group 1: 1 subject received all doses but did not complete the study; Group 2: 2 subjects received all doses but did not complete the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine</title>
            <description>Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)&#xD;
Chloroquine: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
          <group group_id="O2">
            <title>Atovaquone and Proguanil (Malarone)</title>
            <description>Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Atovaquone and Proguanil: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
          <group group_id="O3">
            <title>Doxycycline</title>
            <description>Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Doxycycline: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
          <group group_id="O4">
            <title>Rabies</title>
            <description>RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
        </group_list>
        <measure>
          <title>GMT Over Protective Titer Prior Fourth Dose of PCECV</title>
          <description>Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3, 7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of &gt;0.5 IU/ml against rabies virus as protective.</description>
          <population>Group 1: 1 subject received all doses but did not complete the study; Group 2: 2 subjects received all doses but did not complete the study.</population>
          <units>IU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" spread="289"/>
                    <measurement group_id="O2" value="6.45" spread="1.39"/>
                    <measurement group_id="O3" value="7.04" spread="2.71"/>
                    <measurement group_id="O4" value="6.98" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT Over Protective Titer 28 Days Post Fourth Dose of PCECV</title>
        <description>Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3,7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of &gt;0.5 IU/ml against rabies virus as protective.</description>
        <time_frame>Up to 8 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and up to 6 weeks for Rabies Arm</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine</title>
            <description>Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)&#xD;
Chloroquine: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
          <group group_id="O2">
            <title>Atovaquone and Proguanil (Malarone)</title>
            <description>Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Atovaquone and Proguanil: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
          <group group_id="O3">
            <title>Doxycycline</title>
            <description>Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Doxycycline: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
          <group group_id="O4">
            <title>Rabies</title>
            <description>RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
          </group>
        </group_list>
        <measure>
          <title>GMT Over Protective Titer 28 Days Post Fourth Dose of PCECV</title>
          <description>Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3,7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of &gt;0.5 IU/ml against rabies virus as protective.</description>
          <units>IU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.53"/>
                    <measurement group_id="O2" value="4.96" spread="0.78"/>
                    <measurement group_id="O3" value="5.18" spread="1.14"/>
                    <measurement group_id="O4" value="6.87" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks from Chloroquine, Malarone/Atovaquone, Doxycyline groups, 6 weeks for rabies control group.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chloroquine</title>
          <description>Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)&#xD;
Chloroquine: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
        </group>
        <group group_id="E2">
          <title>Atovaquone and Proguanil (Malarone)</title>
          <description>Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Atovaquone and Proguanil: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
        </group>
        <group group_id="E3">
          <title>Doxyclycline</title>
          <description>Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.&#xD;
RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Doxycycline: FDA approve dosing schedule&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
        </group>
        <group group_id="E4">
          <title>Rabies</title>
          <description>RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.&#xD;
Rabies Vaccine: FDA approve dosing schedule</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <description>Sunburn</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngeal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Timothy Endy</name_or_title>
      <organization>SUNY Upstate Medical University</organization>
      <phone>3154647692</phone>
      <email>endyt@upstate.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

